ClinicalTrials.gg
RecruitingNCT07418385depistageVIHUpdated Feb 18, 2026

Voluntary HIV Screening in the General Population in France

An observational study in Human Immunodeficiency Virus (HIV), sponsored by Université de Reims Champagne-Ardenne. Recruiting at 1 site in France. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-02-18.

Primary conditionAcquired Immunodeficiency Syndrome(the registry's first term)UnverifiedIs this wrong?The registry often attaches Acquired Immunodeficiency Syndrome to studies about something else, and this study's title and listed conditions do not name it. No better condition is named, so the registry's term is kept.

Sponsored by Université de Reims Champagne-Ardenne · Observational

How we know · 2 judgments

From the registry’s dates

  • Primary completion was expected by Apr 2026, 7 months ago, but the record still lists the study as recruiting.
  • Started Oct 2025; still recruiting 1 year 1 month later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Case-only
Time perspective
Cross-sectional
Enrollment
1,000
Ages
18 Years and older
Sex
All
01

Study summary

Since 2020, an increase in positive screenings for sexually transmitted infections, including HIV, has been observed.

Voluntary early screening plays an important role in the national strategy for HIV care in France. There are currently several methods that allow patients to undergo voluntary screening.

Read the detailed description

Objectives

The main objective is to describe the voluntary HIV screening methods used by the general population in France.

02

Conditions studied

  • Human Immunodeficiency Virus (HIV)

Browse trials for

Keywords

  • HIV
  • voluntary screening
03

In context

Acquired Immunodeficiency Syndrome Unverified

3,039 studies on the registry are indexed under Acquired Immunodeficiency Syndrome; 308 are open to participants now.

This study's planned enrollment of 1,000 is above the median of 289 across 504 observational studies indexed under Acquired Immunodeficiency Syndrome.

Browse Acquired Immunodeficiency Syndrome studies →

Lead sponsor

Université de Reims Champagne-Ardenne is the lead sponsor of 64 studies on the registry; 21 are open to participants now.

Compared within Acquired Immunodeficiency Syndrome, the registry's first condition term, which may not be this study's main condition. Counted across the registry records on this site, refreshed daily. How we classify →

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes
Sampling method
Non-probability sample

Study population

Subjects aged 18 years or older, whether or not they have previously undergone voluntary HIV testing, residing in France, and agreeing to participate in the study.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • 18 years of age or older
  • Male or female
  • Regardless of sexual orientation
  • Whether or not they have previously undergone voluntary testing
  • Agreeing to participate in the study.

Exclusion criteria

Exclusion Criteria:

  • Minors
  • Refusing to participate in the study
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Observational model
Case-only
Time perspective
Cross-sectional
Enrollment
1,000 participants (estimated)
Patient registry
No

Interventions

  • Otherdata collections

    data collections

06

What researchers measure

Primary outcomes

  1. The method(s) used for undergoing voluntary HIV testing questionnaire

    The method(s) used for undergoing voluntary HIV testing: medical prescription, Center for Free Information, Testing, and Diagnosis, medical laboratory, rapid diagnostic test (RDT), or self-test

    Time frame: Day 0

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Oct 2025 (actual). Primary completion is estimated for Apr 2026, 6 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 11, 2026
First posted
Feb 18, 2026
StartActual
Oct 7, 2025
Primary completionEst.
Apr 7, 2026
CompletionEst.
Sep 1, 2026
Last update
Feb 18, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 18, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07418385
Lead sponsor
Université de Reims Champagne-Ardenne
Responsible party
Sponsor
First posted
Feb 18, 2026
Start date
Oct 7, 2025
Primary completion
Apr 7, 2026 (estimated)
Completion
Sep 1, 2026 (estimated)
Last update
Feb 18, 2026

Study contacts

Gestonnairedu CURRS
Contact
currs@univ-reims.fr
0326918822 ext. +33

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion